FDA
-
-
-
-
-
-
-
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
-
-
-
-
-
-
-
Acrivon Therapeutics schedules clinical data updates for January
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Acrivon Therapeutics Inc (ACRV)
-
-
-
-
-
-
-
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
-
-
-
-
-
-
-
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
-
-
-
-
-
-
-
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
-
-
-
-
-
-
-
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 I
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

